Public Equities, controls Invus Public Equities and accordingly may be deemed to beneficially own the Shares held by Invus Public Equities. Artal Treasury, as the managing member of Invus PE Advisors, controls Invus PE Advisors, and accordingly may be deemed to beneficially own the Shares that Invus PE Advisors may be deemed to beneficially own. Artal International, as its Geneva branch is the sole stockholder of Artal Treasury, may be deemed to beneficially own the Shares that Artal Treasury may be deemed to beneficially own. Artal International Management, as the managing partner of Artal International, controls Artal International and, accordingly, may be deemed to beneficially own the Shares that Artal International may be deemed to beneficially own. Artal Group, as the parent company of Artal International Management, controls Artal International Management and, accordingly, may be deemed to beneficially own the Shares that Artal International Management may be deemed to beneficially own. Westend, as the parent company of Artal Group, controls Artal Group and, accordingly, may be deemed to beneficially own the Shares that Artal Group may be deemed to beneficially own. The Stichting, as majority shareholder of Westend, controls Westend and, accordingly, may be deemed to beneficially own the Shares that Westend may be deemed to beneficially own. As of January 11, 2021, Mr. Whittouck, as the sole member of the board of the Stichting, controls the Stichting and, accordingly, may be deemed to beneficially own the Shares that the Stichting may be deemed to beneficially own.
(4)
This information is based solely on the information reported on the Schedule 13G filed on February 14, 2019 by Polaris Venture Management Co. VI, L.L.C. 2,676,311 of such shares are held of record by PVP VI and 156,395 of such shares are held of record by PVPFF VI. PVM VI, the general partner of each of PVP VI and PVPFF VI, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, Amir Nashat, a member of the Issuer’s board of directors, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities.
(5)
This information is based solely on the information reported on the Schedule 13G/A filed on February 8, 2021 by FMR LLC.
(6)
This information is based solely on the information reported on the Schedule 13G/A filed on February 16, 2021 by Redmile Group, LLC. Redmile Group, LLC’s beneficial ownership of the Issuer’s common stock (“Common Stock”) is comprised of 2,896,589 shares of Common Stock owned by certain private investment vehicles and/or separately managed accounts managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or separately managed accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.
(7)
This information is based solely on the information reported on the Schedule 13G filed on February 12, 2021 by BB Biotech AG (“BB Biotech”) on behalf of its wholly-owned subsidiary, Biotech Target N.V.
(8)
This information is based solely on the information reported on the Schedule 13G/A filed on February 16, 2021 by T.Rowe Price Associates, Inc.
(9)
This information is based solely on the information reported on the Schedule 13G/A filed on February 2, 2021 by BlackRock, Inc.
(10)
Consists of 15,522 shares of common stock underlying options exercisable within 60 days of March 29, 2021.
(11)
Consists of: (i) 36,245 shares of common stock and (ii) 45,376 shares of common stock underlying options exercisable within 60 days of March 29, 2021.
(12)
Consists of: 20,832 shares of common stock underlying options exercisable within 60 days of March 29, 2021.
(13)
Consists of: (i) 380,491 shares of common stock and (ii) 31,510 shares of common stock underlying options exercisable within 60 days of March 29, 2021.
(14)
Consists of: (i) 290,595 shares of common stock and (ii) 120,034 shares of common stock underlying options exercisable within 60 days of March 29, 2021.